Life Technologies Expands CEERAM Food Safety Range to Global Market

     Life Technologies Expands CEERAM Food Safety Range to Global Market

Award-winning products broaden industry-leading portfolio of food safety

PR Newswire

CARLSBAD, Calif., July 25, 2013

CARLSBAD, Calif., July 25, 2013 /PRNewswire/ --Life Technologies Corporation
(NASDAQ: LIFE) today announced the expansion of its global food safety
portfolio with the worldwide distribution of the RT-qPCR assays for the
detection of Norovirus GI and Norovirus GII, Hepatitis A, and the Mengovirus
Extraction Control Kit by CEERAM(the European Centre for Expertise and
Research on Microbial Agents). Available only in Europe, Middle East and
Africa until now, the solutions will now reach the global market through
Life's supply channels.

Human Norovirus is the most common cause for food-borne disease outbreaks in
the U.S. It causes 800 deaths, around 21 million illnesses and 70,000
hospitalizations each year, according to the Centers for Disease Control and
Prevention (CDC). Globally, tens of millions of individuals contract
Hepatitis A and Norovirus each year. Due to the nature of the virus, molecular
techniques, such as RT-qPCR assays developed by CEERAM, are the most widely
accepted detection method.

"As global leaders in food testing products, we recognise the importance of
public confidence in food safety," said Nir Nimrodi, Life Technologies' Vice
President and General Manager Animal Health & Food Safety. "This global
distribution deal with CEERAM broadens Life Technologies' already extensive
portfolio of pathogen food safety solutions with these virus detection kits,
providing food regulatory bodies and food manufacturers with access to these
high quality products." 

CEERAM will be recognised by the International Association for Food Protection
(IAFP) with a Food Safety Innovations Award during its annual meeting taking
place at the Charlotte Convention Center in Charlotte, N.C., July 28-31. For
more information on CEERAM's RT-qPCR assays for the detection of Norovirus GI
and Norovirus GII, Hepatitis A, and the Mengovirus Extraction Control Kit,
visit the Life Technologies booth (#524) during the conference. 

"CEERAM is taking a great step forward for the distribution of its
CEERAMTools^TM range of RT-qPCR kits with its partner Life Technologies," said
Benoit Lebeau, CEO at CEERAM. "This will increase our market presence and ease
access to new business opportunities."

About Life Technologies
Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company
that is committed to providing the most innovative products and services to
leading customers in the fields of scientific research, genetic analysis and
applied sciences. With a presence in more than 180 countries, the company's
portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents
and licenses that span the entire biological spectrum -- scientific
exploration, molecular diagnostics, 21^stcentury forensics, regenerative
medicine and agricultural research. Life Technologies has approximately 10,000
employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated
results that involve risks and uncertainties. Some of the information
contained in this press release, including, but not limited to, statements as
to industry trends and Life Technologies' plans, objectives, expectations and
strategy for its business, contains forward-looking statements that are
subject to risks and uncertainties that could cause actual results or events
to differ materially from those expressed or implied by such forward-looking
statements. Any statements that are not statements of historical fact are
forward-looking statements. When used, the words "believe," "plan," "intend,"
"anticipate," "target," "estimate," "expect" and the like, and/or future tense
or conditional constructions ("will," "may," "could," "should," etc.), or
similar expressions, identify certain of these forward-looking statements.
Important factors which could cause actual results to differ materially from
those in the forward-looking statements are detailed in filings made byLife
Technologies with the Securities and Exchange Commission.Life Technologies
undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.


Life Technologies Contacts

Mauricio Minotta (U.S.)

David Robertson (EMEA)
+44 141 814 5889

CEERAM Contact

Franck Chatigny
+33 2 40 84 25 39

SOURCE Life Technologies Corporation

Press spacebar to pause and continue. Press esc to stop.